TTBK2 Antibody

What is TTBK2 and what biological functions does it serve?

TTBK2 is a serine/threonine kinase that acts as a critical regulator of ciliogenesis. It controls the initiation of ciliogenesis by binding to the distal end of the basal body and promoting the removal of CCP110, leading to the recruitment of IFT proteins that build the ciliary axoneme . TTBK2 also plays important roles in the tau cascade and in spinocerebellar degeneration . Additionally, it regulates microtubule dynamics in migrating cells through phosphorylation of substrates like KIF2A . Mutations that truncate the C-terminal non-catalytic portion of TTBK2 cause spinocerebellar ataxia type 11 (SCA11), an autosomal dominant inherited movement disorder . Recent studies have also shown that increased levels of TTBK2 expression in kidney carcinoma and melanoma cell lines correlates with resistance to the chemotherapeutic agent Sunitinib .

What is the molecular weight of TTBK2 and how does it appear on Western blots?

TTBK2 has a calculated molecular weight of approximately 137 kDa . On Western blots, it typically appears between 137-150 kDa . When performing Western blot analyses, it's important to use appropriate molecular weight markers and consider that post-translational modifications may affect the apparent molecular weight. TTBK2 has been successfully detected in various cell lines including PC-3, HeLa, and SH-SY5Y cells . For optimal results, most commercial antibodies recommend dilutions ranging from 1:500 to 1:2000 for Western blotting .

What buffer and storage conditions are optimal for TTBK2 antibodies?

Most commercial TTBK2 antibodies are provided in PBS containing 0.02% sodium azide and 50% glycerol at pH 7.3-7.4 . For storage, antibodies should be kept at -20°C where they remain stable for approximately one year after shipment . Aliquoting is generally unnecessary for -20°C storage, though some suppliers recommend it to avoid repeated freeze-thaw cycles . Working dilutions should be prepared fresh in appropriate buffers, typically PBS containing 5% non-fat dried skimmed milk for immunoblotting applications .

What controls should be included when using TTBK2 antibodies in experiments?

When designing experiments with TTBK2 antibodies, the following controls should be included:

• Positive controls: Use cell lines with confirmed TTBK2 expression such as PC-3, HeLa, or SH-SY5Y cells .

• Negative controls: Include samples where TTBK2 is depleted using siRNA, as demonstrated in studies examining KIF2A localization to microtubules .

• Antibody controls: Include a control where the primary antibody is omitted or replaced with non-specific IgG from the same species.

• Knockdown validation: The effectiveness of siRNAs targeting TTBK2 should be confirmed by immunoblot analysis .

• Recombinant protein: Using purified TTBK2 protein as a positive control can help verify antibody specificity.

These controls help ensure the specificity of the observed signals and validity of experimental results.

What are the optimal fixation and sample preparation methods for TTBK2 immunostaining?

For immunofluorescence microscopy detecting TTBK2:

• Cell fixation: Fix cells with 4% paraformaldehyde for 10 minutes at room temperature.

• Washing: Wash twice for 5 minutes with PBS.

• Permeabilization: Permeabilize cells in PBS containing 1% Triton X-100 for 10 minutes at room temperature.

• Blocking: Block with donkey serum (diluted 1:10) for 10 minutes.

• Primary antibody: Incubate with anti-TTBK2 antibody (typically 0.5 μg/ml) for 1 hour.

• Secondary antibody: After washing three times with PBS, incubate with appropriate secondary antibody for 30 minutes .

For immunohistochemistry applications, antigen retrieval with TE buffer at pH 9.0 is suggested, though citrate buffer at pH 6.0 may also be used as an alternative .

How can researchers leverage TTBK2's unique substrate specificity for kinase assays?

TTBK2 has an unusual substrate specificity with preference for a phosphotyrosine residue at the +2 position relative to the phosphorylation site . Based on this knowledge, researchers have developed an optimized peptide substrate (TTBKtide, RRKDLHDDEEDEAMSIYpA) that can be employed to quantify TTBK2 kinase activity .

To perform TTBK2 kinase assays:

• Prepare reaction mixture containing 50 mM Tris/HCl (pH 7.5), 0.1 mM EGTA, 10 mM magnesium acetate, 0.1 mM [γ-³²P]ATP, and the appropriate concentration of peptide substrate.

• When using purified proteins, terminate reactions by applying 40 μl of the reaction mixture onto P81 phosphocellulose paper.

• For immunoprecipitated TTBK2, terminate reactions by adding 10 μl of 0.2 M EDTA and gentle mixing, then spot 50 μl of the reaction onto P81 phosphocellulose paper.

• After extensive washing in 50 mM phosphoric acid, quantify reaction products by Cerenkov counting.

• Calculate Km and Vmax parameters using the Michaelis-Menten model of non-linear regression .

This approach allows for precise measurement of TTBK2 kinase activity in various experimental contexts.

How do SCA11-causing mutations affect TTBK2 detection and activity?

SCA11-causing mutations that truncate the C-terminal non-catalytic moiety of TTBK2 have several important effects that researchers should consider:

• Protein expression: SCA11 truncating mutations enhance TTBK2 protein expression levels .

• Kinase activity: These mutations suppress TTBK2 kinase activity .

• Subcellular localization: Mutations lead to enhanced nuclear localization of TTBK2 .

• Development: In homozygosity, SCA11 mutations cause embryonic lethality at embryonic day 10 .

When studying SCA11 models, researchers should be aware that TTBK2 antibodies targeting different epitopes might show varying results depending on whether the epitope is preserved in the truncated protein. For example, antibodies recognizing N-terminal regions (such as those targeting residues 21-314 or 217-245) would still detect truncated forms , while those targeting C-terminal regions would not detect truncated TTBK2.

What approaches are recommended for studying TTBK2's role in ciliogenesis?

To investigate TTBK2's function in ciliogenesis, researchers can employ several approaches:

• Knockout/knockdown studies: Deplete TTBK2 using siRNA or CRISPR-Cas9 and evaluate effects on cilia formation and function.

• Localization studies: Use immunofluorescence with TTBK2 antibodies (dilution 1:200-1:800) to examine co-localization with basal body markers and ciliary proteins .

• Rescue experiments: Express wild-type or mutant TTBK2 in TTBK2-depleted cells to assess functional rescue of ciliogenesis defects.

• Live imaging: Generate stable cell lines expressing GFP-tagged TTBK2 for live-cell imaging of TTBK2 dynamics during ciliogenesis .

• Mouse models: Study TTBK2 heterozygous or conditional knockout mice, noting that homozygous mutation causes embryonic lethality .

When analyzing ciliogenesis, it's important to consider that TTBK2 controls the initiation of ciliogenesis by binding to the distal end of the basal body and promoting the removal of CCP110, which caps the mother centriole, leading to the recruitment of IFT proteins .

What are common issues in TTBK2 immunoblotting and how can they be resolved?

When performing Western blotting for TTBK2, researchers may encounter several challenges:

For optimal results, use cell lysates (20–30 µg) for SDS-PAGE (10% gels) and transfer onto nitrocellulose membranes. Block for 20 min at room temperature in 10% non-fat dried skimmed milk powder in TBS-T. Use primary antibodies at an optimal concentration (typically 1 µg/ml) in 5% milk in TBS-T .

How can researchers distinguish between TTBK1 and TTBK2 in experimental settings?

TTBK1 and TTBK2 share structural similarities, particularly in their kinase domains, which can present challenges for specific detection:

• Antibody selection: Choose antibodies raised against unique regions of TTBK2 not conserved in TTBK1. The C-terminal region shows homology between TTBK1 and TTBK2, so antibodies targeting unique N-terminal sequences may provide better specificity .

• Molecular weight differences: TTBK2 has a calculated molecular weight of 137 kDa , which can help distinguish it from TTBK1 on Western blots.

• Expression pattern analysis: TTBK1 is predominantly expressed in the brain, while TTBK2 shows a broader expression pattern, which can help distinguish between them in tissue-specific studies.

• Functional validation: Use siRNA knockdown specific to either TTBK1 or TTBK2 to confirm antibody specificity and distinguish their respective functions.

• PCR verification: Complement antibody-based detection with PCR using primers specific to each isoform to confirm their expression levels.

Both TTBK1 and TTBK2 function as regulators of TDP-43 phosphorylation, but they may have distinct roles in different cellular contexts .

What factors should be considered when selecting a TTBK2 antibody for specific applications?

When selecting a TTBK2 antibody for research, consider the following factors:

• Immunogen: Different antibodies are raised against different regions of TTBK2. For example, some antibodies target synthetic peptides between amino acids 217-245 from the N-terminal region , while others target regions like residues 314-385 or Trp21-Thr314 . The choice of immunogen affects specificity and application compatibility.

• Host species: TTBK2 antibodies are available from different host species including rabbit and sheep . Consider the host species when designing multi-color immunofluorescence experiments to avoid cross-reactivity.

• Validated applications: Ensure the antibody has been validated for your specific application:

  • For Western blotting: Antibodies showing clear bands at 137-150 kDa in validated cell lines

  • For immunofluorescence: Antibodies demonstrating specific subcellular localization patterns

  • For immunohistochemistry: Antibodies with validated tissue reactivity and proper controls

• Species reactivity: Verify that the antibody reacts with your species of interest. Most commercial antibodies react with human, mouse, and rat TTBK2 .

• Clonality: Polyclonal antibodies may provide higher sensitivity but potentially lower specificity compared to monoclonal antibodies.

How can TTBK2 antibodies be used to investigate links between ciliogenesis and neurodegeneration?

TTBK2 provides a unique molecular link between ciliogenesis and neurodegeneration, particularly in spinocerebellar ataxia. Researchers can leverage TTBK2 antibodies to explore this connection through:

• Comparative immunohistochemistry: Use TTBK2 antibodies (diluted 1:50-1:500) to compare TTBK2 expression and localization patterns in normal versus SCA11-affected tissues . This can reveal how mutations affect TTBK2 distribution in neuronal cells.

• Ciliary structure analysis: Combine TTBK2 immunofluorescence with ciliary markers to assess how SCA11 mutations impact cilia formation and maintenance in neurons. TTBK2 controls the initiation of ciliogenesis by binding to the basal body and promoting CCP110 removal .

• Mouse model studies: Analyze TTBK2 heterozygous knockin mice carrying SCA11 mutations to understand how altered TTBK2 function affects neurodevelopment and neurodegeneration over time .

• Primary neuronal cultures: Isolate primary neurons from TTBK2 mutant models and use immunofluorescence to study cilia formation, neuronal connectivity, and potential degenerative changes.

• Biochemical pathway analysis: Use TTBK2 antibodies for immunoprecipitation to identify interaction partners in neuronal cells and how these interactions are affected by disease-causing mutations.

This research direction may provide insights into how ciliary dysfunction contributes to neurodegenerative disorders and potentially identify new therapeutic targets.

What methodological approaches can assess TTBK2's role in cancer drug resistance?

Recent studies have indicated that increased TTBK2 expression in kidney carcinoma and melanoma cell lines correlates with resistance to the chemotherapeutic agent Sunitinib . Researchers can investigate this emerging role using:

• Expression correlation studies: Use TTBK2 antibodies for immunohistochemistry on patient-derived tumor samples to correlate TTBK2 expression levels with treatment response and clinical outcomes.

• Functional manipulation: Employ siRNA knockdown of TTBK2 in resistant cancer cell lines to assess sensitization to chemotherapeutic agents, as previous studies showed that reduction of TTBK2 through siRNA sensitized cancer cell lines to Sunitinib .

• Mechanistic investigation: Use co-immunoprecipitation with TTBK2 antibodies to identify interaction partners in drug-resistant versus sensitive cell lines, potentially revealing signaling pathways involved in resistance.

• Phosphorylation targets: Utilize TTBK2's unique substrate specificity (preference for phosphotyrosine at +2 position) to identify potential phosphorylation targets that might mediate drug resistance .

• In vivo models: Develop xenograft models with TTBK2-overexpressing or TTBK2-depleted cancer cells to assess drug response in vivo.

These approaches can help establish TTBK2 as a resistance marker and potential therapeutic target to overcome chemoresistance in cancer treatment.